Evidence map›Paper›PMID 27158037›Full record

ArticleScientific reports2016

Notch2 as a promising prognostic biomarker for oesophageal squamous cell carcinoma.

Cong Wang, Qingbao Li, Fang Liu, Xuan Chen, Bowen Liu, Effat Un Nesa, Shanghui Guan, Lihui Han, Bingxu Tan, Nana Wang and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cong WangDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Qingbao LiDepartment of Cardiac Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, People's Republic of China.
Fang LiuDepartment of Imaging, Shandong Medical College, Jinan, Shandong, 250002, China.
Xuan ChenDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Bowen LiuDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Effat Un NesaDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Shanghui GuanDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Lihui HanDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Bingxu TanDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Nana WangDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Xintong WangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, 250117, China.
Qingxu SongDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Yibin JiaDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Jianbo WangDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Ming LuDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Yufeng ChengDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to examine Notch2 expression in oesophageal squamous cell carcinoma (ESCC) patients and to evaluate its prognostic potential. Immunohistochemical (IHC) staining, quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analysis were utilized to investigate the Notch2 expression status and prognostic value. Furtherly, CCK8 and clonogenic assays were conducted to determine if Notch2 inhibition by shRNA could lead to a decrease in the proliferation and survival of ESCC cells. A notably higher Notch2 expression level was found in ESCC tissues at the mRNA (P < 0.0001) and protein levels (IHC: P = 0.004; western blot: P = 0.021). Log-rank analysis demonstrated that Notch2 overexpression was significantly associated with worse overall survival (OS) (29.1% vs. 49.1%; P = 0.013) and progression-free survival (PFS) (15.3% vs. 34.4%; P = 0.006) rates in ESCC patients. The multivariate analysis revealed Notch2 as an independent prognostic factor for OS and PFS (P = 0.002 and 0.006, resp.). Besides, in vitro assays showed that OD450 values and colony formations were significantly reduced in Notch2-shRNA group (all P < 0.0001). In conclusion, these results show that Notch2 is up-regulated in ESCC tissues and could serve as a promising biomarker for identifying individuals with poor prognostic potential.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellCell Line, TumorCell ProliferationCell SurvivalEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMultivariate AnalysisPrognosisReceptor, Notch2RNA, MessengerRNA, Small InterferingBiomarkers, TumorNOTCH2 protein, humanReceptor, Notch2RNA, MessengerRNA, Small Interfering

Identifiers

PMID27158037
PMCPMC4860585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.